Recently presented preclinical data show that EA Pharma Co. Ltd.'s EA-3571 is a highly potent dual inhibitor of enteropeptidase and trypsin with luminal action, resulting in potential anti-insulin ...

For people with the bleeding disorder hemophilia, life can seem like one continuous state of alertness. If they accidentally ...

Cytokinetics (CYTK) announced that the U.S. Food & Drug Administration has accepted the company’s New Drug Application for aficamten, a ...

After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ ...

PDUFA Target Action Date Set for September 26, 2025SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ...

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...

NEW YORK, Dec. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Elanco Animal health Incorporated ("Elanco" or the "Company") (NYSE: ELAN ) of a class action securities lawsuit.

Minghui Pharmaceutical has reported positive topline outcomes from the randomised Phase III trial of its pan-Jak inhibitor, ...

Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to ...

The controversy erupted on June 26, 2024, when Elanco revealed that Zenrelia's label would include a boxed warning, highlighting safety issues identified during trials with unvaccinated dogs. The ...

A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.

From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light ...